ID   PPAP_HUMAN              Reviewed;         386 AA.
AC   P15309; D3DNC6; Q5FBY0; Q96KY0; Q96QK9; Q96QM0;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-1992, sequence version 3.
DT   10-MAY-2017, entry version 169.
DE   RecName: Full=Prostatic acid phosphatase;
DE            Short=PAP;
DE            EC=3.1.3.2;
DE   AltName: Full=5'-nucleotidase;
DE            Short=5'-NT;
DE            EC=3.1.3.5;
DE   AltName: Full=Ecto-5'-nucleotidase;
DE   AltName: Full=Thiamine monophosphatase;
DE            Short=TMPase;
DE   Contains:
DE     RecName: Full=PAPf39;
DE   Flags: Precursor;
GN   Name=ACPP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=1375464; DOI=10.1016/S0006-291X(05)80048-8;
RA   Sharief F.S., Li S.S.-L.;
RT   "Structure of human prostatic acid phosphatase gene.";
RL   Biochem. Biophys. Res. Commun. 184:1468-1476(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE,
RP   DISULFIDE BONDS, AND ACTIVE SITE.
RX   PubMed=1989985;
RA   van Etten R.L., Davidson R., Stevis P.E., Macarthur H., Moore D.L.;
RT   "Covalent structure, disulfide bonding, and identification of reactive
RT   surface and active site residues of human prostatic acid
RT   phosphatase.";
RL   J. Biol. Chem. 266:2313-2319(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2712834; DOI=10.1016/0006-291X(89)91623-9;
RA   Sharief F.S., Lee H., Leuderman M.M., Lundwall A., Deaven L.L.,
RA   Lee C.-L., Li S.S.-L.;
RT   "Human prostatic acid phosphatase: cDNA cloning, gene mapping and
RT   protein sequence homology with lysosomal acid phosphatase.";
RL   Biochem. Biophys. Res. Commun. 160:79-86(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Prostate;
RX   PubMed=2842184; DOI=10.1016/0014-5793(88)80037-1;
RA   Vihko P., Virkkunen P., Henttu P., Roiko K., Solin T., Huhtala M.L.;
RT   "Molecular cloning and sequence analysis of cDNA encoding human
RT   prostatic acid phosphatase.";
RL   FEBS Lett. 236:275-281(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Prostate;
RX   PubMed=2395659; DOI=10.1093/nar/18.16.4928;
RA   Tailor P.G., Govindan M.V., Patel P.C.;
RT   "Nucleotide sequence of human prostatic acid phosphatase determined
RT   from a full-length cDNA clone.";
RL   Nucleic Acids Res. 18:4928-4928(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=7951074;
RA   Sharief F.S., Li S.S.-L.;
RT   "Nucleotide sequence of human prostatic acid phosphatase ACPP gene,
RT   including seven Alu repeats.";
RL   Biochem. Mol. Biol. Int. 33:561-565(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Sameshima E., Tabata Y., Hayashi A., Iida K., Mitsuyama M., Kanai S.,
RA   Furuya T., Saito T.;
RT   "Acid phosphatase prostate mRNA,nirs splice variant1.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Prostate;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS ASN-15; VAL-124; ARG-226; HIS-330 AND ALA-360.
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   STRUCTURE OF CARBOHYDRATES.
RX   PubMed=3674882; DOI=10.1016/0003-9861(87)90361-4;
RA   Risley J.M., Van Etten R.L.;
RT   "Structures of the carbohydrate moieties of human prostatic acid
RT   phosphatase elucidated by H1 nuclear magnetic resonance
RT   spectroscopy.";
RL   Arch. Biochem. Biophys. 258:404-412(1987).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY, ENZYME REGULATION, AND
RP   MUTAGENESIS OF TRP-206.
RX   PubMed=9584846;
RA   Zhang Z., Ostanin K., Van Etten R.L.;
RT   "Covalent modification and site-directed mutagenesis of an active site
RT   tryptophan of human prostatic acid phosphatase.";
RL   Acta Biochim. Pol. 44:659-672(1997).
RN   [14]
RP   FUNCTION, AND ENZYME ACTIVITY.
RX   PubMed=15280042; DOI=10.1016/j.febslet.2004.06.083;
RA   Tanaka M., Kishi Y., Takanezawa Y., Kakehi Y., Aoki J., Arai H.;
RT   "Prostatic acid phosphatase degrades lysophosphatidic acid in seminal
RT   plasma.";
RL   FEBS Lett. 571:197-204(2004).
RN   [15]
RP   ALTERNATIVE SPLICING, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17638863; DOI=10.1158/0008-5472.CAN-07-1651;
RA   Quintero I.B., Araujo C.L., Pulkka A.E., Wirkkala R.S., Herrala A.M.,
RA   Eskelinen E.-L., Jokitalo E., Hellstroem P.A., Tuominen H.J.,
RA   Hirvikoski P.P., Vihko P.T.;
RT   "Prostatic acid phosphatase is not a prostate specific target.";
RL   Cancer Res. 67:6549-6554(2007).
RN   [16]
RP   PROTEOLYTIC PROCESSING, IDENTIFICATION BY MASS SPECTROMETRY, AND ROLE
RP   IN HIV INFECTION.
RX   PubMed=18083097; DOI=10.1016/j.cell.2007.10.014;
RA   Munch J., Rucker E., Standker L., Adermann K., Goffinet C.,
RA   Schindler M., Wildum S., Chinnadurai R., Rajan D., Specht A.,
RA   Gimenez-Gallego G., Sanchez P.C., Fowler D.M., Koulov A., Kelly J.W.,
RA   Mothes W., Grivel J.C., Margolis L., Keppler O.T., Forssmann W.G.,
RA   Kirchhoff F.;
RT   "Semen-derived amyloid fibrils drastically enhance HIV infection.";
RL   Cell 131:1059-1071(2007).
RN   [17]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B.,
RA   Schaefer H., Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [18]
RP   PROTEOLYTIC PROCESSING, AND ROLE IN XMRV INFECTION.
RX   PubMed=19403677; DOI=10.1128/JVI.00268-09;
RA   Hong S., Klein E.A., Das Gupta J., Hanke K., Weight C.J., Nguyen C.,
RA   Gaughan C., Kim K.A., Bannert N., Kirchhoff F., Munch J.,
RA   Silverman R.H.;
RT   "Fibrils of prostatic acid phosphatase fragments boost infections with
RT   XMRV (xenotropic murine leukemia virus-related virus), a human
RT   retrovirus associated with prostate cancer.";
RL   J. Virol. 83:6995-7003(2009).
RN   [19]
RP   DEGRADATION OF SEVI AMYLOID FIBRILS.
RX   PubMed=19451623; DOI=10.1073/pnas.0811827106;
RA   Hauber I., Hohenberg H., Holstermann B., Hunstein W., Hauber J.;
RT   "The main green tea polyphenol epigallocatechin-3-gallate counteracts
RT   semen-mediated enhancement of HIV infection.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:9033-9038(2009).
RN   [20]
RP   INHIBITION OF SEVI ACTIVITY.
RX   PubMed=19897482; DOI=10.1074/jbc.M109.066167;
RA   Roan N.R., Sowinski S., Munch J., Kirchhoff F., Greene W.C.;
RT   "Aminoquinoline surfen inhibits the action of SEVI (semen-derived
RT   enhancer of viral infection).";
RL   J. Biol. Chem. 285:1861-1869(2010).
RN   [21]
RP   FUNCTION.
RX   PubMed=20498373; DOI=10.1074/jbc.M109.098301;
RA   Chuang T.D., Chen S.J., Lin F.F., Veeramani S., Kumar S., Batra S.K.,
RA   Tu Y., Lin M.F.;
RT   "Human prostatic acid phosphatase, an authentic tyrosine phosphatase,
RT   dephosphorylates ErbB-2 and regulates prostate cancer cell growth.";
RL   J. Biol. Chem. 285:23598-23606(2010).
RN   [22]
RP   TISSUE SPECIFICITY.
RX   PubMed=21487525;
RA   Graddis T.J., McMahan C.J., Tamman J., Page K.J., Trager J.B.;
RT   "Prostatic acid phosphatase expression in human tissues.";
RL   Int. J. Clin. Exp. Pathol. 4:295-306(2011).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) IN COMPLEX WITH
RP   N-PROPYL-L-TARTRAMATE.
RX   PubMed=9804805; DOI=10.1074/jbc.273.46.30406;
RA   Lacount M.W., Handy G., Lebioda L.;
RT   "Structural origins of L(+)-tartrate inhibition of human prostatic
RT   acid phosphatase.";
RL   J. Biol. Chem. 273:30406-30409(1998).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 33-374, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-94 AND ASN-220.
RX   PubMed=10639192;
RX   DOI=10.1002/(SICI)1097-0045(20000215)42:3<211::AID-PROS7>3.0.CO;2-U;
RA   Jakob C.G., Lewinski K., Kuciel R., Ostrowski W., Lebioda L.;
RT   "Crystal structure of human prostatic acid phosphatase.";
RL   Prostate 42:211-218(2000).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 33-386 IN COMPLEX WITH A
RP   PHOSPHATE ION AND INHIBITOR ALPHA-BENZYLAMINOBENZYLPHOSPHONIC ACID,
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-220 AND ASN-333.
RX   PubMed=12525165; DOI=10.1021/bi0265067;
RA   Ortlund E., LaCount M.W., Lebioda L.;
RT   "Crystal structures of human prostatic acid phosphatase in complex
RT   with a phosphate ion and alpha-benzylaminobenzylphosphonic acid update
RT   the mechanistic picture and offer new insights into inhibitor
RT   design.";
RL   Biochemistry 42:383-389(2003).
RN   [26]
RP   STRUCTURE BY NMR OF 248-286.
RX   PubMed=19995078; DOI=10.1021/ja908170s;
RA   Nanga R.P., Brender J.R., Vivekanandan S., Popovych N.,
RA   Ramamoorthy A.;
RT   "NMR structure in a membrane environment reveals putative
RT   amyloidogenic regions of the SEVI precursor peptide PAP(248-286).";
RL   J. Am. Chem. Soc. 131:17972-17979(2009).
CC   -!- FUNCTION: A non-specific tyrosine phosphatase that
CC       dephosphorylates a diverse number of substrates under acidic
CC       conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate
CC       monoesters and phosphorylated proteins. Has lipid phosphatase
CC       activity and inactivates lysophosphatidic acid in seminal plasma.
CC   -!- FUNCTION: Isoform 2: the cellular form also has ecto-5'-
CC       nucleotidase activity in dorsal root ganglion (DRG) neurons.
CC       Generates adenosine from AMP which acts as a pain suppressor. Acts
CC       as a tumor suppressor of prostate cancer through dephosphorylation
CC       of ERBB2 and deactivation of MAPK-mediated signaling.
CC   -!- CATALYTIC ACTIVITY: A phosphate monoester + H(2)O = an alcohol +
CC       phosphate. {ECO:0000269|PubMed:15280042}.
CC   -!- CATALYTIC ACTIVITY: A 5'-ribonucleotide + H(2)O = a ribonucleoside
CC       + phosphate. {ECO:0000269|PubMed:15280042}.
CC   -!- ENZYME REGULATION: Phosphatase activity inhibited by L(+)-
CC       tartrate, and by its derivative, alpha-benzylaminobenzylphosphonic
CC       acid. {ECO:0000269|PubMed:9584846}.
CC   -!- SUBUNIT: Homodimer; dimer formation is required for phosphatase
CC       activity. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-1222012, EBI-1222012;
CC       P04626:ERBB2; NbExp=3; IntAct=EBI-1222012, EBI-641062;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Secreted
CC       {ECO:0000305|PubMed:17638863}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane
CC       {ECO:0000269|PubMed:17638863, ECO:0000269|PubMed:17897319};
CC       Single-pass type I membrane protein {ECO:0000255}. Lysosome
CC       membrane {ECO:0000269|PubMed:17638863,
CC       ECO:0000269|PubMed:17897319}; Single-pass type I membrane protein
CC       {ECO:0000255}. Note=Appears to shuttle between the cell membrane
CC       and intracellular vesicles. Colocalizes with FLOT1 at cell
CC       membrane and in intracellular vesicles (PubMed:17638863).
CC       Colocalizes with LAMP2 on the lysosome membrane (PubMed:17897319).
CC       {ECO:0000269|PubMed:17638863, ECO:0000269|PubMed:17897319}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Secreted PAP, sPAP;
CC         IsoId=P15309-1; Sequence=Displayed;
CC       Name=2; Synonyms=TMPase, TM-PAP, cellular PAP, cPAP;
CC         IsoId=P15309-2; Sequence=VSP_036023;
CC       Name=3;
CC         IsoId=P15309-3; Sequence=VSP_053360;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the prostate, restricted
CC       to glandular and ductal epithelial cells. Also expressed in
CC       bladder, kidney, pancreas, lung, cervix, testis and ovary. Weak
CC       expression in a subset of pancreatic islet cells, squamous
CC       epithelia, the pilosebaceous unit, colonic neuroendocrine cells
CC       and skin adnexal structures. Isoform 2 also expressed in the
CC       sarcolemma of skeletal muscle. Levels of this cellular isoform
CC       decreased in prostate cancer. {ECO:0000269|PubMed:17638863,
CC       ECO:0000269|PubMed:21487525}.
CC   -!- PTM: N-glycosylated. High mannose content, partially sialylated
CC       and fucosylated biantennary complex. Also fucosylated with
CC       partially sialylated triantennary complex oligosaccharides.
CC       {ECO:0000269|PubMed:10639192, ECO:0000269|PubMed:12525165}.
CC   -!- PTM: Proteolytically cleaved in seminal fluid to produce several
CC       peptides. Peptide PAPf39, the most prominent, forms amyloid beta-
CC       sheet fibrils, SEVI (semen-derived enhancer of viral infection)
CC       which entrap HIV virions, attach them to target cells and enhance
CC       infection. SEVI amyloid fibrils are degraded by polyphenol
CC       epigallocatechin-3-gallate (EGCG), a constituent of green tea.
CC       Target cell attachment and enhancement of HIV infection is
CC       inhibited by surfen. Also similarly boosts XMRV (xenotropic murine
CC       leukemia virus-related virus) infection.
CC       {ECO:0000269|PubMed:18083097, ECO:0000269|PubMed:19403677}.
CC   -!- MISCELLANEOUS: Used as a diagnostic tool for staging metastatic
CC       prostatic cancer.
CC   -!- SIMILARITY: Belongs to the histidine acid phosphatase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M97589; AAA60021.1; -; Genomic_DNA.
DR   EMBL; M97580; AAA60021.1; JOINED; Genomic_DNA.
DR   EMBL; M97581; AAA60021.1; JOINED; Genomic_DNA.
DR   EMBL; M97582; AAA60021.1; JOINED; Genomic_DNA.
DR   EMBL; M97583; AAA60021.1; JOINED; Genomic_DNA.
DR   EMBL; M97584; AAA60021.1; JOINED; Genomic_DNA.
DR   EMBL; M97585; AAA60021.1; JOINED; Genomic_DNA.
DR   EMBL; M97586; AAA60021.1; JOINED; Genomic_DNA.
DR   EMBL; M97587; AAA60021.1; JOINED; Genomic_DNA.
DR   EMBL; M97588; AAA60021.1; JOINED; Genomic_DNA.
DR   EMBL; M34840; AAA69694.1; -; mRNA.
DR   EMBL; M24902; AAA60022.1; -; mRNA.
DR   EMBL; X52174; CAA36422.1; -; mRNA.
DR   EMBL; X53605; CAA37673.1; -; mRNA.
DR   EMBL; U07097; AAB60640.1; -; Genomic_DNA.
DR   EMBL; U07083; AAB60640.1; JOINED; Genomic_DNA.
DR   EMBL; U07085; AAB60640.1; JOINED; Genomic_DNA.
DR   EMBL; U07086; AAB60640.1; JOINED; Genomic_DNA.
DR   EMBL; U07088; AAB60640.1; JOINED; Genomic_DNA.
DR   EMBL; U07091; AAB60640.1; JOINED; Genomic_DNA.
DR   EMBL; U07092; AAB60640.1; JOINED; Genomic_DNA.
DR   EMBL; U07093; AAB60640.1; JOINED; Genomic_DNA.
DR   EMBL; U07095; AAB60640.1; JOINED; Genomic_DNA.
DR   EMBL; AB102888; BAD89417.1; -; mRNA.
DR   EMBL; AK300540; BAG62248.1; -; mRNA.
DR   EMBL; AC020633; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79203.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79205.1; -; Genomic_DNA.
DR   EMBL; BC007460; AAH07460.1; -; mRNA.
DR   EMBL; BC008493; AAH08493.1; -; mRNA.
DR   EMBL; BC016344; AAH16344.1; -; mRNA.
DR   CCDS; CCDS3073.1; -. [P15309-1]
DR   CCDS; CCDS46916.1; -. [P15309-2]
DR   CCDS; CCDS77818.1; -. [P15309-3]
DR   PIR; JH0610; JH0610.
DR   RefSeq; NP_001090.2; NM_001099.4. [P15309-1]
DR   RefSeq; NP_001127666.1; NM_001134194.1. [P15309-2]
DR   RefSeq; NP_001278966.1; NM_001292037.1. [P15309-3]
DR   UniGene; Hs.433060; -.
DR   PDB; 1CVI; X-ray; 3.20 A; A/B/C/D=33-374.
DR   PDB; 1ND5; X-ray; 2.90 A; A/B/C/D=33-386.
DR   PDB; 1ND6; X-ray; 2.40 A; A/B/C/D=33-386.
DR   PDB; 2HPA; X-ray; 2.90 A; A/B/C/D=33-374.
DR   PDB; 2L3H; NMR; -; A=248-286.
DR   PDB; 2L77; NMR; -; A=248-286.
DR   PDB; 2L79; NMR; -; A=248-286.
DR   PDB; 2MG0; NMR; -; A=262-270.
DR   PDB; 3PPD; X-ray; 1.50 A; A=260-265.
DR   PDBsum; 1CVI; -.
DR   PDBsum; 1ND5; -.
DR   PDBsum; 1ND6; -.
DR   PDBsum; 2HPA; -.
DR   PDBsum; 2L3H; -.
DR   PDBsum; 2L77; -.
DR   PDBsum; 2L79; -.
DR   PDBsum; 2MG0; -.
DR   PDBsum; 3PPD; -.
DR   DisProt; DP00628; -.
DR   ProteinModelPortal; P15309; -.
DR   SMR; P15309; -.
DR   BioGrid; 106571; 23.
DR   IntAct; P15309; 3.
DR   MINT; MINT-6780778; -.
DR   STRING; 9606.ENSP00000323036; -.
DR   BindingDB; P15309; -.
DR   ChEMBL; CHEMBL2633; -.
DR   DrugBank; DB03577; Alpha-Benzyl-Aminobenzyl-Phosphonic Acid.
DR   DrugBank; DB03390; N-Propyl-Tartramic Acid.
DR   DrugBank; DB06688; Sipuleucel-T.
DR   SwissLipids; SLP:000001295; -. [P15309-1]
DR   DEPOD; P15309; -.
DR   iPTMnet; P15309; -.
DR   PhosphoSitePlus; P15309; -.
DR   BioMuta; ACPP; -.
DR   DMDM; 130730; -.
DR   EPD; P15309; -.
DR   MaxQB; P15309; -.
DR   PaxDb; P15309; -.
DR   PeptideAtlas; P15309; -.
DR   PRIDE; P15309; -.
DR   DNASU; 55; -.
DR   Ensembl; ENST00000336375; ENSP00000337471; ENSG00000014257. [P15309-1]
DR   Ensembl; ENST00000351273; ENSP00000323036; ENSG00000014257. [P15309-2]
DR   Ensembl; ENST00000475741; ENSP00000417744; ENSG00000014257. [P15309-3]
DR   GeneID; 55; -.
DR   KEGG; hsa:55; -.
DR   UCSC; uc003eon.4; human. [P15309-1]
DR   CTD; 55; -.
DR   DisGeNET; 55; -.
DR   GeneCards; ACPP; -.
DR   HGNC; HGNC:125; ACPP.
DR   HPA; CAB000071; -.
DR   HPA; HPA004335; -.
DR   HPA; HPA063916; -.
DR   MIM; 171790; gene.
DR   neXtProt; NX_P15309; -.
DR   OpenTargets; ENSG00000014257; -.
DR   PharmGKB; PA24449; -.
DR   eggNOG; KOG3720; Eukaryota.
DR   eggNOG; ENOG410ZVBQ; LUCA.
DR   GeneTree; ENSGT00530000062956; -.
DR   HOGENOM; HOG000231439; -.
DR   HOVERGEN; HBG002203; -.
DR   InParanoid; P15309; -.
DR   KO; K19283; -.
DR   OMA; RKLIMYS; -.
DR   OrthoDB; EOG091G09FA; -.
DR   PhylomeDB; P15309; -.
DR   TreeFam; TF312893; -.
DR   BRENDA; 3.1.3.2; 2681.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SABIO-RK; P15309; -.
DR   ChiTaRS; ACPP; human.
DR   EvolutionaryTrace; P15309; -.
DR   GeneWiki; Prostatic_acid_phosphatase; -.
DR   GenomeRNAi; 55; -.
DR   PMAP-CutDB; P15309; -.
DR   PRO; PR:P15309; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000014257; -.
DR   CleanEx; HS_ACPP; -.
DR   ExpressionAtlas; P15309; baseline and differential.
DR   Genevisible; P15309; HS.
DR   GO; GO:0035577; C:azurophil granule membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0030175; C:filopodium; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:Ensembl.
DR   GO; GO:0005622; C:intracellular; IDA:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0012506; C:vesicle membrane; ISS:UniProtKB.
DR   GO; GO:0008253; F:5'-nucleotidase activity; IDA:UniProtKB.
DR   GO; GO:0003993; F:acid phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0052642; F:lysophosphatidic acid phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0016791; F:phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:CAFA.
DR   GO; GO:0042131; F:thiamine phosphate phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0046085; P:adenosine metabolic process; IDA:UniProtKB.
DR   GO; GO:0016311; P:dephosphorylation; IMP:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0009117; P:nucleotide metabolic process; IEA:Ensembl.
DR   GO; GO:0060168; P:positive regulation of adenosine receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:CAFA.
DR   GO; GO:0006144; P:purine nucleobase metabolic process; IEA:Ensembl.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IMP:UniProtKB.
DR   GO; GO:0006772; P:thiamine metabolic process; ISS:UniProtKB.
DR   CDD; cd07061; HP_HAP_like; 1.
DR   Gene3D; 3.40.50.1240; -; 1.
DR   InterPro; IPR033379; Acid_Pase_AS.
DR   InterPro; IPR000560; His_Pase_clade-2.
DR   InterPro; IPR029033; His_PPase_superfam.
DR   Pfam; PF00328; His_Phos_2; 1.
DR   SUPFAM; SSF53254; SSF53254; 1.
DR   PROSITE; PS00616; HIS_ACID_PHOSPHAT_1; 1.
DR   PROSITE; PS00778; HIS_ACID_PHOSPHAT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amyloid; Cell membrane;
KW   Complete proteome; Direct protein sequencing; Disulfide bond;
KW   Glycoprotein; Hydrolase; Lysosome; Membrane; Polymorphism;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     32
FT   CHAIN        33    386       Prostatic acid phosphatase.
FT                                /FTId=PRO_0000023963.
FT   PEPTIDE     248    286       PAPf39.
FT                                /FTId=PRO_0000411250.
FT   ACT_SITE     44     44       Nucleophile.
FT                                {ECO:0000269|PubMed:1989985}.
FT   ACT_SITE    290    290       Proton donor.
FT                                {ECO:0000305|PubMed:1989985}.
FT   BINDING      43     43       Substrate.
FT   BINDING      47     47       Substrate.
FT   BINDING     111    111       Substrate.
FT   BINDING     289    289       Substrate.
FT   SITE         49     49       Important for substrate specificity.
FT   SITE        138    138       Required for homodimerization.
FT                                {ECO:0000250}.
FT   SITE        144    144       Required for homodimerization.
FT                                {ECO:0000250}.
FT   SITE        206    206       Required for structural stability.
FT   CARBOHYD     94     94       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:10639192}.
FT   CARBOHYD    220    220       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:10639192,
FT                                ECO:0000269|PubMed:12525165}.
FT   CARBOHYD    333    333       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12525165}.
FT   DISULFID    161    372
FT   DISULFID    215    313
FT   DISULFID    347    351
FT   VAR_SEQ     153    185       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_053360.
FT   VAR_SEQ     380    386       GTEDSTD -> VLKVIFAVAFCLISAVLMVLLFIHIRRGLC
FT                                WQRESYGNI (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_036023.
FT   VARIANT      15     15       S -> N (in dbSNP:rs17850347).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_047960.
FT   VARIANT     124    124       F -> V (in dbSNP:rs17856254).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_047961.
FT   VARIANT     226    226       W -> R (in dbSNP:rs17856253).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_047962.
FT   VARIANT     330    330       Y -> H (in dbSNP:rs17851392).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_047963.
FT   VARIANT     360    360       V -> A (in dbSNP:rs17850198).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_047964.
FT   MUTAGEN     206    206       W->F: Greatly reduced enzyme activity,
FT                                marked decrease in structural stability,
FT                                and increased binding of the inhibitor,
FT                                L(+)-tartrate.
FT                                {ECO:0000269|PubMed:9584846}.
FT   MUTAGEN     206    206       W->L: Reduced enzyme activity, marked
FT                                decrease in structural stability, and
FT                                increased binding of the inhibitor, L(+)-
FT                                tartrate. {ECO:0000269|PubMed:9584846}.
FT   CONFLICT     15     24       SLGFLFLLFF -> AFASCFCFFC (in Ref. 5;
FT                                CAA37673). {ECO:0000305}.
FT   CONFLICT     15     24       SLGFLFLLFF -> ALASCFCFFC (in Ref. 3;
FT                                AAA60022 and 4; CAA36422). {ECO:0000305}.
FT   CONFLICT     46     46       D -> H (in Ref. 5; CAA37673).
FT                                {ECO:0000305}.
FT   CONFLICT     66     73       GFGQLTQL -> RIWPTHPA (in Ref. 5;
FT                                CAA37673). {ECO:0000305}.
FT   CONFLICT     66     73       GFGQLTQL -> WIWPTHPA (in Ref. 4;
FT                                CAA36422). {ECO:0000305}.
FT   CONFLICT     95     95       E -> D (in Ref. 3; AAA60022).
FT                                {ECO:0000305}.
FT   CONFLICT    116    116       A -> R (in Ref. 3; AAA60022).
FT                                {ECO:0000305}.
FT   CONFLICT    139    139       Q -> E (in Ref. 5; CAA37673).
FT                                {ECO:0000305}.
FT   CONFLICT    157    157       P -> R (in Ref. 5; CAA37673).
FT                                {ECO:0000305}.
FT   CONFLICT    212    212       P -> A (in Ref. 4; CAA36422).
FT                                {ECO:0000305}.
FT   CONFLICT    215    215       C -> S (in Ref. 3; AAA60022).
FT                                {ECO:0000305}.
FT   CONFLICT    294    294       S -> T (in Ref. 3; AAA60022).
FT                                {ECO:0000305}.
FT   CONFLICT    372    372       C -> V (in Ref. 3; AAA60022).
FT                                {ECO:0000305}.
FT   CONFLICT    383    383       D -> N (in Ref. 5; CAA37673).
FT                                {ECO:0000305}.
FT   STRAND       34     43       {ECO:0000244|PDB:1ND6}.
FT   HELIX        60     62       {ECO:0000244|PDB:1ND6}.
FT   HELIX        72     88       {ECO:0000244|PDB:1ND6}.
FT   TURN         89     93       {ECO:0000244|PDB:1ND6}.
FT   HELIX        99    101       {ECO:0000244|PDB:1ND6}.
FT   STRAND      102    108       {ECO:0000244|PDB:1ND6}.
FT   HELIX       110    123       {ECO:0000244|PDB:1ND6}.
FT   HELIX       128    130       {ECO:0000244|PDB:1ND6}.
FT   STRAND      134    136       {ECO:0000244|PDB:1CVI}.
FT   STRAND      144    146       {ECO:0000244|PDB:1ND6}.
FT   HELIX       148    150       {ECO:0000244|PDB:1ND6}.
FT   STRAND      152    155       {ECO:0000244|PDB:1ND6}.
FT   HELIX       162    173       {ECO:0000244|PDB:1ND6}.
FT   HELIX       175    181       {ECO:0000244|PDB:1ND6}.
FT   HELIX       182    184       {ECO:0000244|PDB:1ND6}.
FT   HELIX       185    195       {ECO:0000244|PDB:1ND6}.
FT   HELIX       202    208       {ECO:0000244|PDB:1ND6}.
FT   HELIX       210    218       {ECO:0000244|PDB:1ND6}.
FT   HELIX       229    247       {ECO:0000244|PDB:1ND6}.
FT   STRAND      248    251       {ECO:0000244|PDB:1ND6}.
FT   HELIX       252    258       {ECO:0000244|PDB:1ND6}.
FT   HELIX       261    276       {ECO:0000244|PDB:1ND6}.
FT   STRAND      277    279       {ECO:0000244|PDB:1ND5}.
FT   STRAND      282    288       {ECO:0000244|PDB:1ND6}.
FT   HELIX       290    299       {ECO:0000244|PDB:1ND6}.
FT   STRAND      313    321       {ECO:0000244|PDB:1ND6}.
FT   STRAND      324    332       {ECO:0000244|PDB:1ND6}.
FT   STRAND      335    337       {ECO:0000244|PDB:1CVI}.
FT   STRAND      340    342       {ECO:0000244|PDB:1ND5}.
FT   STRAND      349    352       {ECO:0000244|PDB:1ND6}.
FT   HELIX       353    360       {ECO:0000244|PDB:1ND6}.
FT   HELIX       361    363       {ECO:0000244|PDB:1ND6}.
FT   HELIX       368    371       {ECO:0000244|PDB:1ND6}.
SQ   SEQUENCE   386 AA;  44566 MW;  EF81E11DFAECADEA CRC64;
     MRAAPLLLAR AASLSLGFLF LLFFWLDRSV LAKELKFVTL VFRHGDRSPI DTFPTDPIKE
     SSWPQGFGQL TQLGMEQHYE LGEYIRKRYR KFLNESYKHE QVYIRSTDVD RTLMSAMTNL
     AALFPPEGVS IWNPILLWQP IPVHTVPLSE DQLLYLPFRN CPRFQELESE TLKSEEFQKR
     LHPYKDFIAT LGKLSGLHGQ DLFGIWSKVY DPLYCESVHN FTLPSWATED TMTKLRELSE
     LSLLSLYGIH KQKEKSRLQG GVLVNEILNH MKRATQIPSY KKLIMYSAHD TTVSGLQMAL
     DVYNGLLPPY ASCHLTELYF EKGEYFVEMY YRNETQHEPY PLMLPGCSPS CPLERFAELV
     GPVIPQDWST ECMTTNSHQG TEDSTD
//
